TCGA-DK-A1AG-01A-11R-A13Y-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.60446781
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- P53_PATHWAY+0.160
- WNT_BETA_CATENIN_SIGNALING+0.100
- NOTCH_SIGNALING+0.060
- PEROXISOME+0.060
- DNA_REPAIR+0.040
- MYC_TARGETS_V2+0.040
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.040
- PI3K_AKT_MTOR_SIGNALING+0.030
- HEME_METABOLISM+0.010
- TGF_BETA_SIGNALING-0.010
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.490
- PANCREAS_BETA_CELLS-0.450
- CHOLESTEROL_HOMEOSTASIS-0.330
- TNFA_SIGNALING_VIA_NFKB-0.320
- INFLAMMATORY_RESPONSE-0.300
- MTORC1_SIGNALING-0.300
- APOPTOSIS-0.290
- ESTROGEN_RESPONSE_LATE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943008 | — | — | 0.838 |
| 2 | DRR168599 | — | — | 0.837 |
| 3 | TCGA-FD-A43X-01A-11R-A23W-07 | — | — | 0.836 |
| 4 | R247 | — | — | 0.828 |
| 5 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.824 |
| 6 | TCGA-2F-A9KR-01A-11R-A38B-07 | — | — | 0.822 |
| 7 | TCGA-CF-A27C-01A-11R-A16R-07 | — | — | 0.821 |
| 8 | TCGA-LT-A8JT-01A-11R-A36F-07 | — | — | 0.817 |
| 9 | SRR650134 | — | — | 0.816 |
| 10 | MDT-AP-1357 | Med | Medulloblastoma | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.040 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |